SCHEMBL3894146

SCHEMBL3894146

CCN1C(=O)/C(=C\c2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)SC1=S

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 1/20 0.60
▸ MAPT P10636 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ MCL1 Q07820 2/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.56
▸ EIF4E P06730 1/20 0.56
▸ EIF4G1 Q04637 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ MAP3K5 Q99683 5/20 0.55
▸ PKM P14618 1/20 0.53
▸ PTPN7 P35236 1/20 0.53
▸ PTPN12 Q05209 1/20 0.53
▸ PTPN22 Q9Y2R2 1/20 0.53
▸ TNFRSF1A P19438 1/20 0.52
▸ HIF1AN Q9NWT6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3894155 1.00 STAT3 (0.60) STAT3MAPTMEN1ALDH1A1POLB
SCHEMBL6092684 0.94 MAP3K5 (0.59) STAT3MAPTMEN1ALDH1A1POLB
SCHEMBL6092688 0.94 MAP3K5 (0.59) STAT3MAPTMEN1ALDH1A1POLB
SCHEMBL3895615 0.89 MEN1 (0.65) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL3895622 0.89 MEN1 (0.65) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL3897115 0.88 MAPT (0.69) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL3897122 0.88 MAPT (0.69) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL3907023 0.88 POLB (0.61) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL3907019 0.88 POLB (0.61) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL15827143 0.84 STAT3 (0.66) STAT3MAPTMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 STAT3 1781/4885MAPT 1187/4885MEN1 1562/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 STAT3 3636/4885MAPT 880/4885MEN1 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback